America s Voice for Community Health Care

Similar documents
This training will begin at 12:00pm ET. WebEx Technical Support: Or us at

340B Pharmacy Program Compliance insight. ideas Kentucky Primary Care Association attention

6/11/2013. South Carolina Primary Health Care Association. Overview. 340B Essentials. Disclaimer. 340B Essentials. 340B Essentials

340B Drug Pricing Program

The 340B Drug Pricing Program

MATERIAL COVERED TODAY

1/16/2014. David Pointer President, SolutionsRx

340B: WHAT ATTORNEYS NEED TO KNOW TODAY, TOMORROW AND IN THE FUTURE. March 3, 2016 ABA Emerging Issues in Healthcare Conference San Diego, CA

340B Drug Pricing: Don t Become an HRSA Statistic. Wipfli LLP 1

Renee Gravalin, Partner

Table of Contents. Executive Resources, LLC 2015, v. 2

2/25/2016. Today s Objectives. Disclaimer WHAT S NEW IN THE WORLD OF 340B?

A Pharmacy s Guide to 340B Contract Pharmacy Services Best Practices

340B Pharmacy Program Best Practices

BKD NATIONAL HEALTH CARE GROUP

The Federal 340B Drug Discount Program. Compliance and Lessons Learned. Jason Reddish September 24, 2014

Structuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements

THE 340B DRUG DISCOUNT PROGRAM AND INTERPLAY WITH MEDICARE AND MEDICAID REIMBURSEMENT PRINCIPLES. Barbara Straub Williams.

COMPLIANCE IN THE 340B DRUG PRICING PROGRAM

340B Drug Program Compliance: Focus on Disproportionate Hospitals

10/2/2015. CPAs and ADVISORS 340B: COMPLIANCE MATTERS AND HERE S WHY MICHAEL R. EARLS, CPA DIRECTOR. experience access // 2 // experience access

Contract Pharmacy Relationships

340B Program Update & Recommendations for Monitoring Program Compliance October

Chapter 9 Medicaid and 340B

340B Program: Mega Guidance, Mega Change Pershing Yoakley & Associates, PC (PYA).

Webinar Schedule. I. A Guide to the 340B Omnibus Guidance 340B Background Guide to the Guidance

What is the 340B Program?

Introduction. The Basics of the 340B Program. 340B Drug Discount Program Compliance, Audit & Enforcement Activity. Wesley R.

340B Drug Pricing Program: Participation, Eligibility and Program Integrity HOSPITALS June 26 th, 2014

FPNTC FAMILY PLANNING NATIONAL TRAINING CENTER

Statement of Conflicts of Interest

December 1, Maryland Department of Health and Mental Hygiene. Prepared by:

340B MEGA GUIDANCE WHAT NOW? KENTUCKY HFMA WINTER INSTITUTE JANUARY 21, 2016

340B Compliance: Overcoming Challenges with Diversion, Duplicate Discounts, and Orphan Drug Restrictions

340B MEGA GUIDANCE WHAT NOW? HFMA REGION 6 DECEMBER 16, 2015

The 340B drug discount program was created in 1992

An Introduction to and Updated Regarding the 340B Federal Drug Discount Program

The 340B Drug Pricing Program: Opportunities for Community Pharmacists

Following this presentation, attendees should be able to: Identify key events in 340B landscape that occurred in 2015 and 2016.

Pharmaceutical Summit on Business and Compliance Issues in Managed Markets

340B Contract Pharmacy Arrangements: What Does the Future Hold?

Steve Zielinski Regional Director SUNRx, LLC April 16, 2010

TX Health and Human Services Commission Proposed Rule: 340B Program Reimbursement

Medicaid Program; Covered Outpatient Drugs; Proposed Rule (CMS-2345-P) NHIA Summary

340B Program Contract Pharmacy Self-Audit Tool: Diversion

AN ANALYSIS OF TITLE II ROLE OF PUBLIC PROGRAMS

11/5/2015 A&A PERSPECTIVE. HFMA Region 9 Conference November 15, Tracy Young, CPA, Partner Brian Bell, Director

340B Compliance, Audits & Opportunities

RE: 340B Civil Monetary Penalties for Manufacturers and Ceiling Price Regulations (RIN AA89)

340B Program Risk: A Perspective for Pharmaceutical Manufacturers

340B Program New Developments and Increasing Scrutiny

Rx Office Hours: IMPORTANT

Health Policy Explainer

340B Guardian Model Overview

August 11, Submitted electronically via Regulations.gov

Assessing and Maximizing Your Pharmacy Program

Overview of Coverage of Drugs Under the Medicaid Medical Benefit

The Future of 340B. Disclosure

Health Reform Update: Focus on Prescription Drug Price Regulation

Exclusion of Orphan Drugs for Certain Covered Entities under 340B Program

Ryan White & the Affordable Care Act: Frequently Asked Questions

Re: CMS 2238 FC (Final Rule: Medicaid Program; Prescription Drugs)

September 20, Dear Capt. Pedley:

1 INSURANCE SECTION Instructions: This section contains information about the cardholder and their plan identification.

Is Office Ally s EHR Certified for Meaningful Use?

America s Voice for Community Health Care

NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January NCPA Advocacy at Work

Re: CMS-1502-P (Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006)

May 19, As explained more fully below, the 340B Coalition s position on the above three areas is as follows:

The 340B Program: Challenges and Opportunities

December 15, 2017 (31 State SPAs)

How to Survive a HRSA Audit & Take Corrective Action. William von Oehsen, Principal Powers Pyles Sutter & Verville, PC

M E D I C A I D P H A R M A C Y R E I M B U R S E M E N T S T A K E H O L D E R M E E T I N G

CRS Report for Congress Received through the CRS Web

Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis

Texas Vendor Drug Program. Drug Addition Process. Effective Date. December 2017

May 22, Dear Chairman Pai and FCC Commissioners:

Compliance Risk Areas for Health Centers: A Financial Perspective. Marcie H. Zakheim Partner

The Sliding Fee Discount Program: Transitioning from Policy Guidance to Every Day Operations

Center for Medicaid, CHIP, and Survey & Certification SMDL# PPACA# 2. April 22, Re: Medicaid Prescription Drug Rebates

Best Practices for 340B Internal Audits and Key Takeaways from the Winter 340B Coalition Conference

Contract Pharmacy Arrangements in the 340B Program. Conflicts of Interest. Learning Objectives 2/10/2014. OIG Memorandum Report:

THIRD PARTY REIMBURSEMENT OF COVERED ENTITIES: MANUFACTURERS PERSPECTIVE

MEDICARE PART D POLICY FORMULARY: TRANSITION PROCESS Policy Number: 6-C

Operations Manager: H&HS Director:

REPORT OF THE COUNCIL ON MEDICAL SERVICE. (J. Leonard Lichtenfeld, MD, Chair)

ESSENTIAL COMMUNITY PROVIDER PETITION FOR 2017 BENEFIT YEAR FREQUENTLY ASKED QUESTIONS

Big Springs Medical Association, Inc. d/b/a Missouri Highlands Health Care. Independent Auditor s Report and Financial Statements

2019 Transition Policy

NEGATIVE CONSEQUENCES OF THE OHIO PRESCRIPTION DRUG (or Rx) BALLOT ISSUE Families & Children in Medicaid, Pharmacy Services Are Impacted

Moving From PBM to PBA Model

Federal Regulatory Policy Report. Final Medicaid and Exchange Regulations. Implications for Federally Qualified Health Centers

Support and pass provider status legislation in the House and Senate (H.R. 592/S. 109).

Application for Membership

Medicare 340B Drug Changes Effective 1/1/18. Paul Hernandez, Sr. Manager, Business Health nthrive, Inc.

2019 Transition Policy and Procedure

Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016

Florida Medicaid. Prescribed Drugs Services Coverage Policy. Agency for Health Care Administration. Draft Rule

Arkansas Medicaid Health Care Providers - Pharmacy. SUBJECT: PROPOSED - Provider Manual Update Transmittal #74

Before prescribing ZYTIGA (abiraterone acetate), please see accompanying full Prescribing Information. Help simplify starting and staying on ZYTIGA

Transcription:

America s Voice for Community Health Care The National Association of Community Health Centers (NACHC) represents Community and Migrant Health Centers, as well as Health Care for the Homeless and Public Housing Primary Care Programs and other community-based health centers. Founded in 1971, NACHC is a nonprofit advocacy organization providing education, training and technical assistance to health centers in support of their mission to provide quality health care to medically underserved populations.

The NACHC Mission To promote the provision of high quality, comprehensive and affordable health care that is coordinated, culturally and linguistically competent, and community directed for all medically underserved populations.

For further information about NACHC and America s Health Centers Visit us at www.nachc.com

NACHC 340B Webinar Series Part 1: Basics of the 340B Drug Pricing Program Cynthia (Cindy) R. DuPree Partner, Draffin & Tucker, LLP January 20, 2016

This is the first in a series of four webinars. Today we will focus on 340B Basics. Due to the number of callers, and the complexity of the 340B Program, please limit questions to the material covered in today s webinar. We will compile all unanswered questions from today s webinar and respond to them as soon as possible.

What is the 340B Drug Program?

340B Program Program that allows certain entities to buy drugs at discounted prices Savings from lower drug costs can then be used to expand FQHC services or reduce charges to patients

Medicaid Drug Rebate Program - 1990 Required drug manufacturers to have a rebate agreement with the government in order for their drugs to be covered under Medicaid

Although drug manufacturers offered the rebates, provider costs for other discounted drugs rose dramatically.

340B Drug Program - 1992 Congress then created the 340B Drug Program to protect certain clinics and hospitals (known as covered entities) from significant drug price increases.

340B Drug Program - 1992 A second agreement was signed by the drug manufacturers which limited the amount that could be charged to covered entities for drugs. This is known as the ceiling price.

Ceiling price calculation

Ceiling price calculation Average Manufacturer Price (AMP) Unit price, net of discounts, that distributors pay for the retail community pharmacies

Ceiling price calculation Unit Rebate Amount (URA) Percentage discount allowed off of the AMP Calculated by the Centers for Medicare and Medicaid Services Based on drug classes Brand 23.1% Generic 13.0% Clotting Factor 17.1% Exclusively Pediatric 17.1%

Ceiling price calculation Average manufacturer price $1.00 minus: Unit rebate amount* (Brand).23 340B ceiling price for one pill $.77 *Brand 23.1% Generic 13.0% Clotting Factor 17.1% Exclusively Pediatric 17.1% Calculation example does not consider other factors such as best price, consumer price index and base line AMPs.

Ceiling price calculation HRSA (Health Resources Services Administration) calculates the ceiling prices each quarter.

Verification of ceiling price

What s the benefit? The FQHC benefits by saving the difference between the usual drug cost and the 340B cost. (340B savings) Many insurers will continue to pay the FQHC the normal reimbursement rate for the drug, regardless of the 340B reduced cost.

Why do FQHCs participate? 340B savings enable the covered entities to provide increased services to patients. FQHCs can offer lower prescription costs. According to a NACHC study, FQHC s drug costs could increase by a minimum of 41% if 340B pricing was not used.

Prime Vendor Program By participating in the 340B Prime Vendor Program, covered entities can save more on the cost of drugs. The PVP can negotiate prices even lower than the ceiling price. (subceiling prices)

How can 340b savings be used?

Intent of Program To permit covered entities to stretch scarce Federal resources as far as possible, reaching more eligible* patients and providing more comprehensive services. H.R. Rep. No. 102-384(II), at 12 (1992) *340B patient eligibility criteria does not require that the patient is indigent or qualifies for a sliding fee scale discount.

Use of 340B savings? Law does not specify further. Savings may be passed on to the patient. Drug Discount Cards Sliding Fees Savings may go into operations to expand programs and services.

FQHCs Are statutorily required to invest all revenues, including 340B, into activities that are approved under their HRSA/Bureau of Primary Health Care Scope of Project and advance their charitable mission.

Document use of 340B savings Policies and procedures should discuss use of the savings and how such use supports intent of Program. Are savings passed directly to patients? Are savings used in programs to benefit the low-income and underserved populations?

Who can participate in the 340B Program?

Covered entities A non-profit healthcare organization, that meets certain Federal designations, or receives specific types of Federal funding may participate. FQHCs and FQHC look-alikes are both eligible.

How does the Program work?

340B process flow Register in OPA Database Distribute to 340B eligible patients Bill to patient Obtain approval from HRSA Place in 340B inventory Collect amounts owed Notify manufacturer /supplier Purchase discounted drugs Use 340B savings

COMPLIANCE ISSUES! Register in OPA Database Distribute to 340B eligible patients Bill to patient Obtain approval from HRSA Place in 340B inventory Collect amounts owed Notify manufacturer /supplier Purchase discounted drugs Use 340B savings

How do you register?

Where to register Web-based https://opanet.hrsa.gov/340b/default

Quarterly registration windows Registration Period Effective Date January 1-15 April 1 April 1-15 July 1 July 1-15 October 1 October 1-15 January 1

Information needed

Parent and child sites The main FQHC site is the parent. Delivery sites at different physical addresses from parent are known as child sites. Each site must be separately registered. Parent Child Child Child

Attestation

More registration information https://opanet.hrsa.gov/opa/manuals/public/ce7registerce.pdf

What is recertification?

Why recertify annually? Opportunity to review and update OPA database Re-attest to compliance No recertification..no participation!

When to recertify? FQHCs usually recertify in February.

More recertification information https://opanet.hrsa.gov/opa_mod/manuals/public/cerecertify.pdf

What drugs can be discounted under 340B?

Covered 340B drugs No vaccines!

Who is an eligible patient?

Current definition 61 Fed. Reg. 55156, October 24, 1996

Multiple hurdles Provider Prescriber Encounter type and location Once a patient, always a patient? What if prescriber leaves practice? How many refills are eligible? What about referrals? Is there a need for underlying diagnosis to be treated during encounter?

Employees & 340B Employees must meet the qualifying patient definition, same as any other patient. Source: Apexus FAQ

How are 340b drugs distributed to patients?

Drug delivery models Contract In-house

How do you track 340B inventory?

Types of 340B inventory systems Physically separate Virtual model

Types of inventory systems Physically separate Often used for in-house pharmacies. One inventory can be used if all patients are 340B eligible. Two inventories will be needed, separate 340B and non- 340B, if some patients are ineligible for 340B program. Patient eligibility is determined at time of drug dispense or administration.

Physical inventory Pre-purchased inventory model (physical inventory) 340B Covered entity patients Non-340B Other patients

Types of inventory systems Virtual model Used mostly in contract pharmacy arrangements. 340B and non-340b inventory is commingled. Patient eligibility is retrospectively determined. Tracking software will be needed.

Virtual inventory tracking In a virtual, commingled inventory, drugs are designated 340B after the drug is purchased and dispensed. Tracking system will be necessary. Must be tracked and replenished by National Drug Code (NDC) number

NDC matching is required National Drug Code 11 digit number First 5 digits = manufacturer Next 4 digits = drug product Final 2 digits = package size

Why is NDC matching important? National Drug Code 11 digit number First 5 digits = manufacturer Next 4 digits = drug product Final 2 digits = package size A manufacturer does not want to give a rebate to the State, or a discount on replenishment, if the drug dispensed was not purchased from that manufacturer.

What is a contract pharmacy?

Covered entities that participate in the Program may contract with retail pharmacies to dispense 340B drugs on their behalf.

Pros and cons - contract pharmacy Provides alternative if no in-house pharmacy is available Increases patient access to medications Eliminates cost of operating in-house pharmacy Reduces amount of 340B savings Requires tracking software Increases compliance concerns

The OIG issued a Memorandum Report: Contract Pharmacy Arrangements in the 340B Program on February 4, 2014.

340B and Medicaid

Who gets the 340B savings on Medicaid patients? Carve-in Dispense 340Bpurchased drugs to Medicaid patients Bill Medicaid program Must following individual State s billing rules for 340B drugs Example: (Acquisition cost + processing fee) Carve-out Does not dispense 340B-purchased drugs to Medicaid patients State bills manufacturer for rebate amount

Medicaid Exclusion File http://opanet.hrsa.gov/opa/cemedicaidextract.aspx

HRSA Clarification Medicaid managed care patients are considered Medicaid patients. Entities must have separate Medicaid numbers if some sites carve-in and some carve-out or are not otherwise 340B eligible sites. http://www.hrsa.gov/opa/programrequirements/policyreleases/clarificationmedicaidexclusion.pdf

What and where are the 340B rules?

Program Guidance

Want to learn more?

NACHC Information NACHC website guidance Upcoming webinars 1/27 Contract Pharmacy 2/03 Recent Developments 2/10 Compliance/Self-audits

For more information or questions: Cindy DuPree Draffin & Tucker, LLP Atlanta, Georgia cdupree@draffin-tucker.com NACHC and America s Health Centers www.nachc.com